The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

The American Diabetes Association (ADA) and the European Association for the Study of
Diabetes (EASD) convened a writing group to develop a consensus statement on the …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …

Type 1 diabetes mellitus is believed to result from destruction of the insulin-producing β-cells
in pancreatic islets that is mediated by autoimmune mechanisms. The classic view is that …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling
pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T …